Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Nephros Inc.

NEPH

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.

Last trade $2.86
Day change -$0.14 (-4.67%)
Day range $2.82 – $3.00
Volume 85,875
Market cap $33M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$32.61M
Price / earnings
17.06×
Price / book
2.6×
Price / sales
1.51×
EV / sales
1.3×
EV / EBITDA
14.81×

Profitability

Earnings per share
$0.18
Return on assets
12.49%
Return on equity
15.23%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
5.5×
Quick ratio
3.45×
Cash ratio
1.89×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$910K

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NEPH, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$5.62M$6.02M$5.21M$4.73M$4.76M$4.42M$4.88M$3.87M
Cost of revenue$2.34M$1.99M$2.22M$1.97M$1.85M$1.62M$1.72M$1.4M
Gross profit$3.29M$4.03M$2.99M$2.76M$2.92M$2.8M$3.15M$2.48M
Selling, general and administrative$2.43M$2.42M$2.52M$2.32M$2.23M$2.2M$2.25M$1.87M
Research and development$331K$366K$346K$395K$338K$311K$295K$252K
Total operating expenses$2.79M$2.81M$2.9M$2.74M$2.6M$2.55M$2.59M$2.16M
Operating income$501K$1.21M$97K$18K$314K$248K$566K$317K
Interest expense$0-$1K$0$0$0-$1K$0$0
Income before taxes$512K$1.21M$140K$62K$340K$246K$558K$364K
Income taxes$0$13K$0$0$3K$9K$0$15K
Net income$512K$1.2M$140K$62K$337K$237K$558K$349K
Net income attributable to common shareholders$512K$1.2M$140K$62K$337K$237K$558K$349K
EBITDA$480K$1.24M$124K$50K$283K$281K$606K$352K
Basic earnings per share$0.05$0.11$0.01$0.01$0.03$0.02$0.05$0.03
Diluted earnings per share$0.05$0.11$0.01$0.01$0.03$0.02$0.05$0.03

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

New Strong Buy Stocks for November 12th

Zacks has added five stocks to its Strong Buy list based on significant increases in consensus earnings estimates over the last 60 days. The stocks span multiple sectors including dry bulk shipping, restaurant retail, biopharmaceuticals, medical devices, and educational technology.

Zacks Investment Research

Nephros Inc. (NEPH) Tops Q3 Earnings and Revenue Estimates

Nephros Inc. (NEPH) reported Q3 2026 earnings of $0.05 per share, beating consensus estimates of $0.02 and representing a 150% surprise. Revenue of $5.62 million also exceeded expectations by 6.68%. However, the stock has declined 33.4% year-to-date versus the S&P 500's 12.3% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, and operates in the Medical-Products industry which ranks in the bottom 36% of Zacks industries.

Zacks Investment Research

Envista (NVST) Tops Q3 Earnings and Revenue Estimates

Envista (NVST) reported Q3 earnings of $0.40 per share, beating consensus estimates of $0.35, with revenues of $691.5 million slightly exceeding expectations. The company has outperformed the market by 14.1% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market. The Medical-Products industry ranks in the bottom 37% of Zacks industries.

Zacks Investment Research

QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue Estimates

QuidelOrtho reported Q3 2026 earnings of $0.31 per share, beating consensus estimates of $0.18 by 72%, though revenues slightly missed expectations at $618.9M. Despite the earnings beat, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The stock has underperformed the market by 50.9% year-to-date, and the Medical-Products industry ranks in the bottom 35% of Zacks industries.

GlobeNewswire Inc.

Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET

Nephros, Inc. (Nasdaq: NEPH), a water technology and filtration solutions company, announced that its President and CEO Robert Banks will present at Maxim Group LLC's virtual 'Health, Wellness & Longevity' conference on July 22, 2026, at 10:00 a.m. ET. The conference brings together leaders from companies innovating in beverages, food, supplements, and longevity sectors to discuss consumer preferences and emerging trends.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 10, 20191-for-9reverse split
Mar 17, 20111-for-20reverse split